G protein-coupled receptors (GPCRs) represent a large family of seven transmembrane receptors, which communicate extracellular signals into the cellular lumen. The human genome contains 720-800 GPCRs, and their diverse signal characteristics are determined by their specific tissue and subcellular expression profiles, as well as their coupling profile to the various G protein families (Gs, Gi, Gq, G12). The G protein coupling pattern links GPCR activation to the specific downstream effector pathways. G12/13 signalling of GPCRs has been studied only recently in more detail, and involves activation of RhoGTPase nucleotide exchange factors (RhoGEFs). Four mammalian RhoGEFs regulated by G12/13 proteins are known: p115-RhoGEF, PSD-95/Disc-large/ZO-1 homology-RhoGEF, leukemia-associated RhoGEF and lymphoid blast crisis-RhoGEF. These link GPCRs to activation of the small monomeric GTPase RhoA, and other downstream effectors. Misregulated G12/13 signalling is involved in multiple pathophysiological conditions such as cancer, cardiovascular diseases, arterial and pulmonary hypertension, and bronchial asthma. Specific targeting of G12/13 signalling-related diseases of GPCRs hence provides novel therapeutic approaches. Assays to quantitatively measure GPCR-mediated activation of G12/13 are only emerging, and are required to understand the G12/13-linked pharmacology. The review gives an overview of G12/13 signalling of GPCRs with a focus on RhoGEF proteins as the immediate mediators of G12/13 activation.
calcium-sensing receptors, KSHV-ORF74 chemokine receptors, NK1 tachykinin receptors and thyroid-stimulating hormone (TSH) receptors (Katoh et al., 1996; Sauzeau et al., 2000; Komatsuzaki et al., 2001; Thevananther et al., 2001; Greenberg et al., 2003; Zheng et al., 2003; Riobo and Manning, 2005; Hains et al., 2006; Alexander et al., 2008) . G12/13 coupling can be predicted using a hidden Markov model algorithm based on the presence of certain amino acid sequences (Sgourakis et al., 2005) . All known G12/13-linked GPCRs signal additionally through other types of G proteins such as Gi/o and/or Gq/11, but GPCRs uniquely coupling to G12/13 may have been missed in the past as assay technologies for their readout evolved only recently (Riobo and Manning, 2005; Siehler, 2008) . Activation of G12/13-coupled GPCRs causes activation of heterotrimeric G12 and/or G13 proteins (Figure 1 ). The activated and guanosine triphosphate (GTP)-bound a subunit is thought to dissociate from the bg dimer, and its activity is terminated upon GTP hydrolysis (Hepler and Gilman, 1992) . Ga12 and Ga13 were discovered in 1991 as a fourth class of Ga proteins. They are ubiquitously expressed and mouse isoforms reveal 67% homology (Strathmann and Simon, 1991; Offermanns, 2003) . N terminal palmitoylation is relevant for plasma membrane attachment and receptor interactions. Their slow guanosine diphosphate (GDP)/GTP exchange rate indicates their importance in prolonged signalling (Dhanasekaran and Dermott, 1996) .
'Regulator of G protein signalling' (RGS) proteins further regulate the activity of G proteins, mostly as GTPaseactivating proteins (GAPs) accelerating G protein inactivation, or they can enhance G protein function (Zhong and Neubig, 2001; Xie and Palmer, 2007) . RGS proteins for G 12/13 proteins are RhoGEFs, four of which are known to be regulated by G12-type proteins: p115-RhoGEF, PSD-95/Disc-large/ ZO-1 homology (PDZ)-RhoGEF, leukemia-associated RhoGEF (LARG) and lymphoid blast crisis (Lbc)-RhoGEF. They function as GAPs towards Ga12/13, and binding to Ga12/13 stimulates their guanine nucleotide exchange factor (GEF) activity (Fukuhara et al., 2001; Dutt et al., 2004) . RhoGEF catalyses the exchange of GDP for GTP by promoting an active conformation of the small monomeric GTPase RhoA (Sah et al., 2000; Wheeler and Ridley, 2004) . Upon activation by Ga12/13 RhoGEF translocates from the cytosol to the plasma membrane (Meyer et al., 2008) . Oligomerization of RhoGEF negatively regulates its activity, which may prevent interaction with RhoA (Chikumi et al., 2004; Baisamy et al., 2005) . Activation of RhoA is further regulated by guanine nucleotide dissociation inhibitors (GDIs), which bind to the C terminus of RhoA, where they mask the geranylgeranyl residue responsible for membrane association. RhoGDI release is required for RhoA activation, and it extracts RhoA from membranes for subsequent inactivation. Moreover, RhoGAP proteins inactivate RhoA by accelerating intrinsic GTPase activity (Fukuhara et al., 2001; Wheeler and Ridley, 2004) . RhoA regulates multiple downstream effectors including many cytoskeletal proteins, and most of these have not been studied in detail. Research has elucidated RhoA-mediated activation of Rho
Figure 1 G12/13-RhoGEF-RhoA signalling pathway. GPCR-activated G12/13-proteins mediate translocation of RhoGEF from the cytosol to the plasma membrane, and stimulate its GEF activity. RhoGEFs oligomerize in their inactive form, and active monomers bind via their RGS domains to active Ga12/13 at the plasma membrane. RhoGEF reveals GAP activity towards Ga12/13, and induces downstream activation of the monomeric GTPase RhoA. Active GTP-bound RhoA is released from its inhibitory protein RhoGDI, and anchors to the plasma membrane through its geranylgeranyl-residue. Downstream targets of RhoA include ROCK, which mediates cell contraction through inhibition of MLC phosphatase, and increased SRF-dependent gene transcription. GAP, GTPase-activating protein; GDI, guanine nucleotide dissociation inhibitor; GEF, guanine nucleotide exchange factor; GPCR, G protein-coupled receptor; GTP, guanosine triphosphate; MLC, myosin light chain; RGS, regulator of G protein signaling; ROCK, Rho kinase; SRF, serum response factor.
Regulation of RhoGEF by G12/13-GPCRs kinases (ROCK1/2) and certain downstream pathways. ROCK phosphorylates the focal adhesion kinase (FAK), which leads to formation of actin stress fibres, and to activation of the 'serum response' transcription factor SRF. SRF binds in the nucleus to serum response element (SRE) sequences in the promoter of specific genes, and regulates their transcription (Narumiya et al., 1997; Treisman et al., 1998; Riento and Ridley, 2003) . ROCK causes on the other hand inhibition of myosin light chain (MLC) phosphatase and direct phosphorylation of MLCs. The increase of phosphorylated MLCs in the cytoskeleton induces cell contraction (Narumiya et al., 1997; Riento and Ridley, 2003) . Described cellular phenomena caused by the G 12/13-RhoGEF-RhoA pathway of GPCRs hence often involve signalling or contraction through cytoskeletal proteins.
G12/13-regulated RhoGEF proteins
GPCRs coupled to G12/13 proteins activate the RhoGEF family members p115-RhoGEF, PDZ-RhoGEF, LARG and Lbc-RhoGEF (Fukuhara et al., 2001; Dutt et al., 2004) . RhoGEFs are large proteins, and human p115-RhoGEF, PDZ-RhoGEF and LARG consist of 927, 1522 and 1544 amino acids respectively. LbcRhoGEF has multiple splice variants present in various tissues, and the unspliced form consists of 893 amino acids (Table 1) . The amino acid identity of human p115-RhoGEF and human PDZ-RhoGEF, LARG and Lbc-RhoGEF is 36%, 39% and 31% respectively. All four RhoGEFs are widely expressed in mammals (Fukuhara et al., 2001; Dutt et al., 2004) . High transcript levels of p115-RhoGEF are present in hematopoietic cells, and of PDZ-RhoGEF in the central nervous system (Kuner et al., 2002) . The Lbc-RhoGEF splice variant A-kinase anchoring protein (AKAP)-Lbc is highly expressed in the heart. AKAPs bind the regulatory subunit type II of the cyclic adenosine monophosphate-dependent protein kinase A (PKA) anchoring it at specific subcellular sites, but additionally function as scaffold proteins for other signalling complexes (Diviani et al., 2001; 2004) .
All four RhoGEFs contain an RGS domain to directly interact with G 12/13 and to exert GAP activity towards G12/13 The RGS sequence homology to classical RGS proteins is rather low. Whereas p115-RhoGEF, PDZ-RhoGEF and LARG contain the RGS domain in the N terminal sequence, Lbc-RhoGEF has a C terminal region sharing 39% amino acid identity to the consensus RGS domain and hence called 'RGS-like'. Nevertheless, the homology of the RGS domain of p115-RhoGEF with those of PDZ-RhoGEF and LARG is also only 32% and 41% respectively (Hart et al., 1996; Kozasa et al., 1998; Wells et al., 2002; Dutt et al., 2004) . Two other common motifs of RhoGEF proteins in the C terminal region are the Dbl-homology (DH) and pleckstrin-homology (PH) domains. The DH domain specifically binds to and stabilizes nucleotide-and Mg 2+ -free RhoA transition states to enhance its nucleotide exchange. Cells contain higher levels of GTP as compared with GDP, and the RhoGEF DH domain therefore induces loading of RhoA with GTP, and its transition into an active state (Rossman et al., 2005) . The PH domain is essential for full GEF activity, and moreover anchors RhoGEF to other signalling proteins to trigger specific subcellular localizations (Fukuhara et al., 2001; Dutt et al., 2004) . PDZ-RhoGEF and LARG additionally contain an N terminal PDZ domain, which enables coupling to cell surface receptors such as plexins, insulin-like growth factor receptors or GPCRs (Fukuhara et al., 2001; Taya et al., 2001; Chikumi et al., 2004; Dutt et al., 2004; Yamada et al., 2005; Grabocka and Wedegaertner, 2007; Kelly et al., 2007) . The G protein-coupled LPA 1 and LPA2 receptors were shown to directly interact through their C terminal PDZ domainbinding motifs with the PDZ domain of LARG and PDZRhoGEF to activate RhoA (Yamada et al., 2005) , and it remains to be seen whether further GPCRs can directly interact with these RhoGEFs.
p115-RhoGEF localizes throughout the cytosol, and rapidly translocates to the plasma membrane upon GPCR-activation of Ga12/13, or expression of constitutively active Ga12/13 mutants (Bhattacharyya and Wedegaertner, 2003a; Meyer et al., 2008 ). An E229L mutation of Ga13 disrupted p115-RhoGEF interaction and recruitment to the plasma 
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membrane (Grabocka and Wedegaertner, 2005) . E27 and E29 in the acidic-rich N terminus of p115-RhoGEF are besides the RGS and PH domains required for binding to activated Ga13, but not for plasma membrane translocation (Bhattacharyya and Wedegaertner, 2003a,b) . LARG is reported to be distributed throughout the cytoplasm in most cells, except of Madin-Darby canine kidney cells, in which LARG is localized at lateral membranes. In fibroblasts, LARG was reported to localize to the microtubule-organizing centre and along microtubule tracks to contribute to cell polarity. PDZRhoGEF localizes in some cell types also in the cytosol, but in others at the cell periphery at or near the plasma membranes where it interacts with cortical actin. In polarizing neutrophils, PDZ-RhoGEF localizes to the back of the cells. Activation of PDZ-RhoGEF and LARG by Ga 12/13 induces their translocation to the plasma membrane (Banerjee and Wedegaertner, 2004; Wong et al., 2007; Goulimari et al., 2008; Meyer et al., 2008) . The subcellular localization of LARG and PDZ-RhoGEF might depend on PDZ-interacting proteins present in a cell. Ga12 and Ga13 specifically interact with distinct splice variants of Lbc-RhoGEF, and cause redistribution of Lbc-RhoGEF from the cytosol to the plasma membrane (Diviani et al., 2001; 2004) . The localization of all RhoGEFs specifically controls the spacial distribution of RhoA activity in cells. Ga13, but not Ga12, was found to stimulate the GEF activity of p115-RhoGEF and PDZ-RhoGEF Tanabe et al., 2004) . Ga12 is reported to enhance the GEF activity of tyrosine-phosphorylated LARG, but not of unphosphorylated LARG. Ga13 on the other hand enhances more weakly both phosphorylated and unphosphorylated forms of LARG . Ga12/13 enhance the GEF activity of the Lbc-RhoGEF splice variant AKAP-Lbc through triggering the release of PKA, which inhibits its GEF activity by phosphorylation and concomitant recruitment of 14-3-3 (Diviani et al., 2001; Kurose, 2003; Diviani et al., 2004) . Stimulation of RhoGEF activities by kinases include tyrosine phosphorylation of PDZ-RhoGEF and LARG by FAK or Tec (Fukuhara et al., 2001; Suzuki et al., 2003; Chikumi et al., 2004) , and serine phosphorylation of p115-RhoGEF by protein kinase C (PKC)a (Holinstat et al., 2003) . p21-activated kinase (PAK)1 can bind to the DH/PH domains of p115-RhoGEF (but not of LARG or PDZ-RhoGEF), and mediate Rac-induced inhibition of RhoA activation (Rosenfeldt et al., 2006) .
RhoGEFs were recently found to oligomerize through their C terminus, which inhibits their GEF activity and interaction with RhoA. Oligomerization was not affected by interaction with Ga 12/13. p115-RhoGEF and AKAP-Lbc form homooligomers, whereas PDZ-RhoGEF and LARG can form homo-and heterooligomers. Blockade of AKAP-Lbc oligomerization abolished the inhibitory effect of PKA and 14-3-3 (Chikumi et al., 2004; Baisamy et al., 2005) . RhoGEFs can compete with other RGS proteins for binding to Ga12/13, which can prevent RhoA activation (Kelly et al., 2007) . Examples are axin which blocks Ga12-p115-RhoGEF interaction, and RGS16 that prevents Ga13-p115-RhoGEF interaction (Johnson et al., 2003; Stemmle et al., 2006) . Mutant RhoGEFs lacking GEF activity function as dominant-negative inhibitors of GPCR-or G12/13-mediated responses, whereas constitutively active p115-RhoGEF, lacking the N and C terminal regulatory domains, activates RhoA (Mao et al., 1998; Fukuhara et al., 1999; Lee et al., 2004) . G 12/13-regulated RhoGEFs all activate RhoA, but are not completely redundant. Using small interfering ribonucleic acid, the thrombin receptor was found to signal through LARG to activate RhoA, whereas the LPA receptor utilized PDZ-RhoGEF .
Only limited genetic mouse models and genetic linkages are known for the four G12/13-regulated RhoGEFs. Knockout mice are described for p115-RhoGEF, but not yet for PDZ-RhoGEF, LARG and Lbc-RhoGEF. The murine homologue of human p115-RhoGEF, Lsc, is solely expressed in hematopoietic cells. Lsc-knockout mice reveal impaired B/T lymphocyte proliferation, and B cell homing (Francis et al., 2006) . Moreover, a mutant form of LARG has been found in some human cancers such as acute myeloid leukemia (Kourlas et al., 2000) . In the worm species Caenorhabditis elegans only one RGS-containing RhoGEF exists, RHGF-1, that is a homologue of the mammalian p115-RhoGEF. RHGF-1 is regulated by the Ga12 homologue GPA-12, and causes activation of the RhoA homologue RHO-1. RHO-1 has been characterized to regulate neuronal activity such as acetylcholine release and locomotion (McMullan and Nurrish, 2007) .
Downstream signalling of RhoGEF proteins
The G12/13-regulated RhoGEFs, p115-RhoGEF, PDZ-RhoGEF, LARG and Lbc-RhoGEF, cause activation of RhoA. Three closely related isoforms of Rho exist: RhoA, RhoB and RhoC, which are ubiquitously expressed, share 85% amino acid sequence identity, and have a C terminal geranylgeranyl residue. RhoA plays a key role in the regulation of the actin cytoskeleton, cell shape, cell polarity, microtubule dynamics, membrane transport pathways, gene transcription, cell adhesion, cell migration, neurite extension/retraction and cell growth. The roles of RhoB and RhoC are less clear. Activation of RhoA by a G12/13-linked GPCR induces its redistribution to the plasma membrane, which is reversed by injection of RhoGDI (Michaelson et al., 2001; Bhattacharya et al., 2004; Wheeler and Ridley, 2004; Wennerberg and Der, 2004; Yonemura et al., 2004; Jaffe and Hall, 2005; Rossman et al., 2005) . Three RhoGDI proteins are described, and only RhoGDIa is ubiquitously expressed and has the highest affinity for RhoA. Phosphorylation of RhoGDIa by PKCa causes activation of RhoA, whereas phosphorylation by PKA causes RhoA inhibition (Mehta et al., 2001; Jaffe and Hall, 2005) . Binding of GTP to RhoA causes its conformational change, and subsequent interaction with effector proteins (Bhattacharya et al., 2004) . C3 toxin specifically ADP-ribosylates RhoA at N41 in the effector domain and inactivates RhoA. It is utilized to detect involvement of RhoA in signalling (Jaffe and Hall, 2005) . The RhoA-S19N dominant-negative mutant has decreased affinity for GTP, and increased affinity for RhoGEFs. The GTPase activity of RhoA is impaired by G14V or G63L mutations, and these result in a constitutively active mutant (Seasholtz et al., 1999) . Mutant RhoA forms do not bind RhoGDI, and localize at the plasma membrane and internal membranes (Jaffe and Hall, 2005) .
Many effector proteins of RhoA have been found, but only a few have been further studied. The best characterized RhoA Regulation of RhoGEF by G12/13-GPCRs 44 Sandra Siehler effectors, ROCK1/2, are ubiquitously expressed serine/ threonine kinases, which translocate from the cytosol to the plasma membrane in the presence of active RhoA (Narumiya et al., 1997) . Binding to RhoA disrupts the interaction between the ROCK kinase domain and its autoinhibitory C terminal domain. ROCK-mediated effects can be prevented by the selective and adenosine triphosphate-competitive ROCK inhibitor fasudil (Y27632) (Sah et al., 2000) . ROCK phosphorylates many substrates such as FAK, c-Jun N-terminal kinase (JNK), MLC phosphatase, ezrin/radixin/moesin (ERM), LIM kinase (LIMK), Diaphanous (mDia), rhophilin, rhotekin, citron kinase and microtubule-associated Tau. In neurons, ROCK inactivates collapsin response mediator protein-2 (CRMP-2), which leads to blockade of microtubule assembly and hence neurite retraction (Sah et al., 2000; Jaffe and Hall, 2005) . Phosphorylated FAK enhances formation of focal extracellular matrix adhesions of cells, complexes additionally containing paxillin, talin, a-actinin and vinculin, among other proteins. Focal adhesions link actin stress fibres to certain integrins at the inner surface of the plasma membrane, and p115-RhoGEF, PDZ-RhoGEF and LARG activation were demonstrated to be involved in focal adhesion formation and movement (Dubash et al., 2007; Iwanicki et al., 2007) . Phosphorylated active JNK causes downstream phosphorylation of the transcription factors Jun and ATF2, and hence regulates gene transcription (Kurose, 2003) . As previously described, ROCK inhibits MLC phosphatase by phosphorylation of the regulatory myosin-binding subunit of myosin phosphatase (MYPT1), which results in enzymatic inhibition. The resulting increased levels of the phosphorylated regulatory light chain MLC20 of myosin II enhances actomyosin crossbridging which leads to cell contraction in different cell types (Narumiya et al., 1997) . The ERM protein family links plasma membrane proteins with the actin cytoskeleton. ERM proteins are relevant in cell adhesion, cell migration and cell division, and are stabilized by ROCK through phosphorylation (Kurose, 2003; Kelly et al., 2007) .
Serum response factor-dependent gene transcription is controlled by two RhoA-dependent pathways: (i) activated ROCK/LIMK stabilize F-actin by blocking the depolymerizing factor cofilin; and (ii) active mDia1/vasodilator-stimulated phosphoprotein enhance F-actin assembly by promoting filament nucleation. The resulting G-actin depletion induces activation of SRF. The transcription factor SRF binds as a dimer to SREs together with a co-transcription factor ['ternary complex factor' (TCF) like e.g. Elk-1] regulated by the Ras/Raf/ extracellular signal-regulated kinase pathway. SRF controls expression of immediate-early and muscle-specific genes, including the cytoskeletal proteins b-actin and vinculin (Marinissen and Gutkind, 2005) . A SRF-dependent reporter gene assay has been invented by mutation of the TCF-binding site in the c-fos SRE, and has been widely used to indirectly detect RhoA activation. The canonical SRE core sequence CC[A/T] 6GG represents the DNA-binding site for SRF. Another SRF cofactor, MAL, dissociates from cytosolic actin monomers to translocate to the nucleus upon RhoA activation. The transcription of different SRF target genes requires specific SRF cofactors (Treisman et al., 1998; Jaffe and Hall, 2005) . SRF is activated not only by G12/13-linked GPCRs, active Ga12/13 proteins and RhoA, but also by overexpression of p115-RhoGEF, PDZ-RhoGEF and LARG (Seasholtz et al., 1999; Chikumi et al., 2004; Wang et al., 2004) .
Gene deletion studies in mice revealed differences of G 12 versus G13 (Offermanns, 1999; Kelly et al., 2007) ; however, no effector has been identified that is uniquely activated by either G protein. A few GPCRs apparently couple only to either G protein, such as 5-HT4 and LPA2 receptors linked to G13, or the PAR-1 receptor linked to G12. PAR-1 in another cell type, however, coupled also to G13, and these apparent specificities might be cell type or assay-dependent (Gu et al., 2002; Moers et al., 2003; Yamaguchi et al., 2003; Riobo and Manning, 2005) . Differences in ligand potencies and efficacies dependent on G12 versus G13 were reported for the 'thromboxane' TXA2 receptor in a Ga subunit-specific guanosine-5′-O-(3′ -[ 35 S]thio)-triphosphate ([ 35 S]GTPgS) binding assay. Ligands were only weakly active or inactive at the TXA2 receptor upon coexpression or receptor fusion of Ga12, but potent in the presence of Ga13 (Zhang et al., 2006) . Not only G12 versus G13 activation, but also RhoGEF and downstream effector activation differences might be explained by ligand-effector trafficking, i.e. selective ligand potencies towards specific effector pathways.
Measurement of G12/13-dependent RhoGEF activation
Multiple assay technologies are available since many years to measure Gs-, Gi-or Gq-type signalling of GPCRs. In contrast, readouts to measure modulation of the G12/13-RhoGEFRhoA pathway emerged only recently (Siehler, 2008) . Initially, RhoA antibodies have been used to immunoprecipitate RhoA, and to measure [ 35 S]GTPgS or [ 32 P]GTP binding. This was hampered by the lack of specificity of available RhoA antibodies versus other small RhoGTPases, and by the small signals due to a high GTP hydrolysis rate of RhoA (Seasholtz et al., 1999) . Similar assays were developed to directly detect activation of G12/13 by using specific antibodies. Stimulated cells are lysed, and [
35 S]GTPgS binding is measured either at immunoprecipitated Ga12/13, or at Ga12/13 immunocaptured with antibody-linked scintillation proximity assay (SPA) beads (Barr et al., 1997; Milligan, 2003; DeLapp, 2004) (Figure 2 ). All these methods were either not quantitative, or in the case of the [ 35 S]GTPgS SPA assay the assay window was only limited. Another method to detect RhoA activation uses the Rho binding domain (RBD) of the effector Rhotekin to specifically extract active RhoA-GTP, and to detect levels by immunoblot detection (Ren and Schwartz, 2000) . The rapid GTP hydrolysis rate and immunodetection do not allow a true quantification of signals to characterize GPCR-related pharmacology.
A quantitative method was invented using an SRF-specific reporter gene readout with a mutated c-fos promoter SRE that only binds SRF dimers but no co-transcription factor (Mao et al., 1998; Treisman et al., 1998) . Nevertheless, the assay window is limited, and the RhoA-dependent activation of SRF is also modulated by other pathways. Fluorescent biosensors were developed to measure RhoA activation by detection of RhoA-GTP. One biosensor consists of four fused proteins, Regulation of RhoGEF by G12/13-GPCRs Sandra Siehler namely yellow fluorescent protein (YFP), the RBD of protein kinase N, truncated RhoA (amino acids 1-189) and cyan fluorescent protein (CFP). Active RhoA within the fusion protein binds the RBD of protein kinase N, and the proximity of the two fluorophores leads to an intramolecular fluorescence resonance energy transfer (FRET) signal that can be measured using subcellular confocal imaging. Another biosensor contains fused Rhotekin-RBD, CFP, YFP and C-terminal fulllength RhoA, that is, the fluorophores were placed in the centre to allow RhoA to bind to RhoGDI (Yoshizaki et al., 2003; Pertz et al., 2006) . These biosensors have the potential for quantitative FRET measurements using high content screening; however, only single cell analyses have been demonstrated so far.
A quantitative drug screening assay for G 12/13 activation by GPCRs was recently established, and detects translocation of 'enhanced green fluorescent protein'-tagged p115-RhoGEF. Alternatively, p115-RhoGEF can be visualized by immunostaining using a specific antibody. p115-RhoGEF translocates from the cytosol to the plasma membrane upon activation by G12/13-linked GPCRs, and signals can be recorded in a kinetic fashion. Translocation signals are measured using subcellular confocal imaging, and signals are quantified using suitable software algorithms for data analysis. All tested G12/13-coupled GPCRs mediated translocation of p115-RhoGEF. Co-expression of wildtype Ga12 or Ga13 allows to distinguish between G12-versus G13-dependent p115-RhoGEF translocation. The RhoGEF translocation assay enables compound screening and the discovery of GPCR ligands active in a G12/13-linked disease context (Meyer et al., 2008) .
Dysfunction of the G12/13-RhoGEF pathway
Misregulation of G12/13 signalling of GPCRs causes multiple pathophysiological conditions, which underlines the important role of the G12/13-RhoGEF-RhoA pathway in physiological processes (Siehler, 2007; Worzfeld et al., 2008) . Some of these are reviewed in more detail. In many types of smooth muscle cells (SMCs) (vascular, coronary, bronchial, cerebral, visceral and gastric) the G12-RhoA-ROCK axis causes sustained contraction through MLC phosphatase inhibition, whereas Ca 2+ -MLC kinase regulates transient contraction. ROCK inhibitors act on vascular SMCs to prevent vasoconstriction, and are in the clinic for arterial hypertension therapy (Watterson et al., 2005; Wettschureck and Offermanns, 2005; Brown et al., 2006) . Development of arterial hypertension in a salt-induced mouse model was shown to require G12/13-LARG signalling in vascular SMCs (Wirth et al., 2008) . Moreover, ROCK inhibitors are effective for treatment of cerebral vasospasm, pulmonary arterial hypertension and asthma by preventing contraction of cerebral and bronchial SMCs respectively (Calo and Pessina, 2007) . Other data indicate a role of ROCK in coronary artery spasm and hence ischemic heart disease due to constriction of human coronary artery SMCs (Ohmori et al., 2003) . In myocardial infarction, RhoA and ROCK expression is up-regulated and causes cardiomyocyte apoptosis, and RhoA activation induces hypertrophy of primary cardiomyocytes (Brown et al., 2006; del Re et al., 2007) . Dominant-negative p115-RhoGEF blocks hypertrophic responses in cardiac myocytes (Kurose, 2003) . Transgenic expression of active Ga 13 or of RhoA in the heart causes cardiac hypertrophy, and p115-RhoGEF is up-regulated in FRET signals between the donor CFP and acceptor YFP occur upon binding of the effector RBD to activated (GTP-bound) RhoA, and can be quantified using fluorescence imaging. Activation of RhoA can be indirectly measured in an SRF-dependent reporter gene assay. CFP, cyan fluorescent protein; EGFP, enhanced green fluorescent protein; FRET, fluorescence resonance energy transfer; GEF, guanine nucleotide exchange factor; GPCR, G protein-coupled receptor; GTP, guanosine triphosphate; GTPgS, guanosine-thio triphosphate; SPA, scintillation proximity assay; SRF, serum response factor; YFP, yellow fluorescent protein.
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Sandra Siehler hypertrophic cardiomyocytes (Wettschureck and Offermanns, 2005; Brown et al., 2006; Porchia et al., 2008) .
In the immune system, the G12/13-RhoA axis is relevant in the regulation of lymphocyte adhesion and migration, and neutrophil chemokinesis and chemotaxis. Lsc/p115-RhoGEFknockout mice reveal defective B-cell homing and T-and B-cell proliferation (Wettschureck and Offermanns, 2005; Francis et al., 2006) . G12/13 signalling is required for splenic B cell maturation, migration and polarization (Rieken et al., 2006) . G13 and RhoA are further required for platelet activation, shape change and aggregation, and hence for wound healing (Moers et al., 2003; Kelly et al., 2007) . Constitutively active Ga12/13 proteins were found to be oncogenes in various cell types. No Ga12/13 mutations have been identified in various tumours of cancer patients, but instead increased expression of Ga12/13 and RhoA could be detected breast, prostate and colon tumours. RhoA is involved in carcinogenesis and cancer progression. Cell adhesion is reduced, which promotes cell migration and invasion of breast, prostate and colon cancer cells, and ultimatively leads to metastatic tumour progression (Kurose, 2003; Wettschureck and Offermanns, 2005; Kelly et al., 2006; 2007) . Further literature data support a role of the G12/13-RhoA axis in ovarian and lung cancer (Kelly et al., 2007; Touge et al., 2007) .
The G12/13-RhoGEF-RhoA pathway of GPCRs therefore is implicated in many diseases including cardiac hypertrophy, cardiac failure, ischemic heart disease, arterial and pulmonary hypertension, bronchial asthma, inflammatory diseases, stroke, cancer progression and metastasis.
Conclusions
G12/13-signalling of GPCRs represents an emerging research area. Whereas aspects of G12/13 have been studied in greater detail in cellular systems and various tissues over the past years (Riobo and Manning, 2005; Worzfeld et al., 2008) , the coupling potential of many GPCRs to this class of G proteins has often not been examined. Even less clear is the involvement of specific RhoGEF proteins and effectors in downstream signalling events. A few GPCRs were found to couple solely to G12 or G13 (Gu et al., 2002; Moers et al., 2003; Yamaguchi et al., 2003) , although these specificities have been neither studied in various cell types, nor at the level of various downstream readouts. All four known G12/13-regulated RhoGEFs, p115-RhoGEF, PDZ-RhoGEF, LARG and LbcRhoGEF, are activated by G13. p115-RhoGEF and PDZ-RhoGEF on the other hand also translocate in the presence of GPCRactivated G12, but do not reveal any GEF activation by G12 Tanabe et al., 2004; Meyer et al., 2008) . Other factors such as kinases regulate the activity of RhoGEFs. Besides specificities towards G12 versus G13 regulation of RhoGEFs, two G12/13-linked GPCRs have been discovered to signal specifically through one RhoGEF versus another . On the other hand, no specific effector protein uniquely activated by either G12 or G13, or by either RhoGEF protein is known so far.
Understanding the complexity of the specific regulation of G12/13, RhoGEF proteins and RhoA-linked effectors is required to interpret pharmacological differences of G12/13-coupled GPCRs in various primary cell systems and tissues. Future research on the G 12/13-RhoGEF-RhoA pathway of GPCRs is needed to further elucidate molecular pathways and their physiological context, which will facilitate the development of innovative therapies for patients.
